BioCorteX is a digital medicine company that has developed a "techbio" platform to model the complex interactions between the microbiome, host, and treatment, ultimately helping clinicians personalize treatment. The company's flagship product, Carbon Mirror, uses technology incorporating principles of physics and chemistry to create in-silico simulations with high fidelity, to assess and predict an individual's response to treatment based on their microbiome profile. This will ultimately enable a new paradigm of personalized care, bringing benefits to people living with diseases in treatment decisions, pharma companies in clinical trial designs, and ultimately to payers by ensuring a patient receives the most relevant and effective therapy available.
What is the problem?
To date, drug development largely ignores drug-bacteria interactions resulting in trials needlessly failing and a seemingly random response in people living with diseases. The interaction between the microbiome and its host is complex and remains a challenging question that requires an entirely new approach.
What is their solution?
We exist because current drug development fails individuals by ignoring the (un)desirable drug-microbiome interactions. Our key product, CarbonMirror uses deep tech and AI to simulate how the colossal number of microbiota interact with therapeutics, de-risking (pre-)clinical trials and replacing uncertainty with confidence for the patient. CarbonMirror technology can be applied to medications, cosmetics, personal care, manufacturing, and agriculture. BioCorteX is a 'techbio' that applies deep technology to deliver effective therapeutics by leveraging the synergy between health and bacteria, viruses, and fungi. BioCorteX is developing a human-microbiome platform intended to deliver therapeutics by leveraging the synergy between therapeutics and bacteria. Our platform utilizes deep tech and artificial intelligence to simulate the colossal number of microbiota-drug interactions.
